Volume 30, No 7, Jul 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 7, July 2020: 556-557

RESEARCH HIGHLIGHTS

A β-galactosidase kiss of death for senescent cells

Xiaoqian Liu^1,2,3 , Juan Carlos Izpisua Belmonte⁴ , Weiqi Zhang^1,5,6,7,8,* , Guang-Hui Liu^1,3,7,8,*

¹Advanced Innovation Center for Human Brain Protection, and National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital Capital Medical University, 100053 Beijing, China;
²State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 100101 Beijing, China;
³State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, 100101 Beijing, China;
⁴Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA;
⁵Disease Genomics and Individualized Medicine Laboratory, Beijing Institute of Genomics, Chinese Academy of Sciences, 100101 Beijing, China;
⁶China National Center for Bioinformation, 100101 Beijing, China;
⁷Institute for Stem cell and Regeneration, Chinese Academy of Sciences, 100101 Beijing, China ;
⁸University of Chinese Academy of Sciences, 100049 Beijing, China
Correspondence: Weiqi Zhang(zhangwq@big.ac.cn)Guang-Hui Liu(ghliu@ioz.ac.cn)

In a recent paper published in Cell Research , Cai et al. report development of the prodrug senescence-specific killing compound 1 (SSK1), which specifically clears SA-β-galactosidase-positive senescent cells both in vitro and in vivo. By activation of the p38 MAPK pathway and induction of cellular apoptosis, SSK1 functions broadly to attenuate chronic inflammation and improve physiological function.

https://doi.org/10.1038/s41422-020-0325-6

FULL TEXT | PDF

Browse 957